Zealand Pharma launches equity offering



Denmark-based Zealand Pharma A/S has announced an offering of new shares which is expected to raise DKK 6.3 billion ($900 million). This will be done by way of a private placement directed at institutional and professional investors in Denmark and elsewhere. Zealand Pharma is one of a growing number of companies developing new drugs for obesity and fibrosis. Its peptide-based medicines, also intended to treat rare diseases, include two marketed products and three in late-stage development.